Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?
Furberg
Curt D
CD
Department of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1063, USA. cfurberg@wfubmc.edu
Psaty
Bruce M
BM
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000592:standards / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions; D019317:Evidence-Based Medicine / Q000592:standards*; D006801:Humans; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control; D004364:Pharmaceutical Preparations / Q000145:classification / Q000592:standards*; D020521:Stroke / Q000401:mortality / Q000517:prevention & control; D013810:Therapeutic Equivalency; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D004364:Pharmaceutical Preparations